Wellington Management Group
GLUE icon

Wellington Management Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Wellington Management Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.02M Buy
207,427
+78,635
+61% +$1.49M ﹤0.01% 1443
2026
Q1 		$2.12M Sell
128,792
-19,265
-13% -$368K ﹤0.01% 1541
2025
Q4 		$2.32M Sell
148,057
-10,467
-7% -$141K ﹤0.01% 1565
2025
Q3 		$1.17M Sell
158,524
-66,294
-29% -$351K ﹤0.01% 1744
2025
Q2 		$1.01M Buy
224,818
+37,087
+20% +$165K ﹤0.01% 1719
2025
Q1 		$871K Sell
187,731
-34,010
-15% -$209K ﹤0.01% 1730
2024
Q4 		$1.54M Buy
221,741
+4,740
+2% +$35.6K ﹤0.01% 1637
2024
Q3 		$1.15M Buy
217,001
+50,330
+30% +$254K ﹤0.01% 1683
2024
Q2 		$623K Buy
166,671
+46,024
+38% +$235K ﹤0.01% 1755
2024
Q1 		$851K Buy
+120,647
New +$716K ﹤0.01% 1719
2021
Q3 		– Sell
-9,192
Closed -$209K – 2190
2021
Q2 		$209K Buy
+9,192
New +$187K ﹤0.01% 2087

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group's GLUE Position: Q2 2026 in Review

Wellington Management Group increased its Monte Rosa Therapeutics (GLUE) stake by 61% in Q2 2026, buying an estimated $1.49M and bringing the position to 207,427 shares worth $5.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

Wellington Management Group first reported a position in GLUE in Q2 2021 and has held it in 11 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Wellington Management Group held 207,427 shares of Monte Rosa Therapeutics worth $5.02M as of Q2 2026.
  • Wellington Management Group bought 78,635 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.49M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1443 holding.
  • Wellington Management Group first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.